Physician profile
John A Hoffman
NPI 1457335689
$8,137.98
in general payments reported to CMS, 2019-2025
31 companies · $14.20 in 2025
The $14.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $1,593 · 2021: $2,867 · 2022: $1,854 · 2023: $19.92 · 2024: $14.39 · 2025: $14.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,250.98 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $909.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $866.05 | 2019-2022 | |
| Abbvie INC. | $854.93 | 2020-2022 | |
| Amgen INC. | $627.97 | 2019-2022 | |
| Pfizer INC. | $508.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.38 | 2019-2022 | |
| Lilly USA, LLC | $451.08 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $331.79 | 2020-2021 | |
| Glaxosmithkline, LLC. | $311.12 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $258.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.73 | 2019-2022 | |
| Abbott Laboratories | $156.60 | 2021-2022 | |
| Esperion Therapeutics, INC. | $153.37 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $125.89 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $80.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.69 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $50.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.98 | 2020-2021 | |
| Allergan, INC. | $40.61 | 2020 | |
| Genentech USA, INC. | $37.88 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.00 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $19.92 | 2023 | Trudhesa |
| Boston Scientific Corporation | $16.58 | 2022 | |
| Dexcom, INC. | $15.61 | 2021 | |
| Sumitomo Pharma America, INC. | $14.20 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $12.72 | 2022 | |
| Astellas Pharma US INC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.